|View printer-friendly version|
|March 19, 2009 4:57 p.m.|
|Teva and Medicis Announce Settlement Agreement|
Jerusalem, Israel and Scottsdale, Arizona, March 19, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Medicis Pharmaceutical Corporation (NYSE: MRX) today announced they have agreed to terminate all legal disputes between them relating to SOLODYN® (minocycline HCl, USP) Extended Release Tablets. Pursuant to an agreement entered into between the parties, Teva has confirmed that Medicis' patents relating to SOLODYN® are valid and enforceable, and cover Teva's activities relating to its generic product under Abbreviated New Drug Application (ANDA) #65-485. As part of the settlement, Teva has agreed to immediately stop all further shipments of generic SOLODYN®. Medicis has agreed to release Teva from liability arising from any prior sales of its generic SOLODYN®, which were not authorized by Medicis.